The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz, MD, Justus-Liebig University, Giessen, Germany, discusses the Phase II KEYNOTE-667 study (NCT03407144) which assessed the use of pembrolizumab plus cyclophosphamide, vincristine, prednisone/prednisolone, and dacarbazine (COPDAC-28) consolidation in children and young adults with high-risk classical Hodgkin lymphoma (cHL) who exhibited a slow early response (SER) to frontline chemotherapy with vincristine, etoposide, prednisone/prednisolone, and doxorubicin (OEPA). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
